Search Results

BACKGROUND: The aim of this study is to compare duration of analgesia and incidence of adverse effects between two doses of intrathecal morphine in patients after elective ceasrean section. METHODS: Group 1 (n = 31) received morphine 0.1 mg and group 2 (n = 28) received morphine 0.2 mg in addition to intrathecal dose of 2.0 ml of 0.5% bupivacaine in 8% dextrose and fentanyl 15ng. RESULTS: In both groups 1 and 2, excellent postoperative analgesia with long duration was obtained (19.4 +/- 10.1 and 20.5 +/- 11.3 hours, respectively). Fourteen patients (45.2%) in group 1 and 12 patients (42.9%) in group 2 developed mild pruritus that did not require treatment except one patient in group 2 who received nalbuphine 5 mg iv. Incidences of postopertaive nausea or vomiting were not significantly different between the two groups. CONCLUSIONS: Both small doses intrathecal morphine of 0.1 mg and 0.2 mg provided adequate analgesia and patient satisfaction postoperatively with same incidences of side effects.
Analgesia* ; Bupivacaine ; Cesarean Section ; Female ; Fentanyl ; Glucose ; Humans ; Incidence ; Morphine* ; Nalbuphine ; Nausea ; Patient Satisfaction ; Pregnancy ; Pruritus ; Vomiting

10.Short-term Effect of Intravitreal Bevacizumab Injection Preventing Panretinal Photocoagulation-Induced Macular Edema in Proliferative Diabetic Retinopathy.

Jung Sub KIM ; Ho RA

Journal of the Korean Ophthalmological Society 2009;50(8):1197-1203

PURPOSE: To investigate the effect of intravitreal bevacizumab injection in preventing panretinal photocoagulation (PRP)-induced macular edema and visual dysfunction in proliferative diabetic retinopathy. METHODS: We conducted a prospective study of 40 consecutive eyes (20 patients) with proliferative diabetic retinopathy whose visual acuity (logMAR) was 0.2 or less, foveal thickness (microm) was 280 or less, and retinopathy was bilaterally symmetrical. In Group 1 (20 eyes), PRP was performed with intravitreal bevacizumab injection 1 week before the initiation of PRP, but in Group 2 (20 eyes) PRP alone was performed. In all eyes, PRP was completed using the same technique. Best corrected visual acuity (BCVA) and foveal and parafoveal thicknesses were measured before treatment and 1 and 3 months after PRP. RESULTS: Before treatment, the mean BCVA and foveal and parafoveal thicknesses were not statistically significantly different between the two groups (p>0.05). At 1 and 3 months after PRP, the mean BCVA improved and the foveal and parafoveal thicknesses were significantly smaller in Group 1 than in Group 2 (p<0.05). CONCLUSIONS: Intravitreal bevacizumab injection before PRP could help prevent PRP-induced macular edema and visual dysfunction in patients with proliferative diabetic retinopathy and good vision.
Antibodies, Monoclonal, Humanized ; Diabetic Retinopathy ; Eye ; Humans ; Light Coagulation ; Macular Edema ; Prospective Studies ; Vision, Ocular ; Visual Acuity ; Bevacizumab

1.Obesity in School-age Children.

2.A Study on Plasma Antidiuretic Hormone and Serum Sodium Levels of Cord Blood in the Newborn Infants.

3.A Clinical Study on Patients with Mycoplasma Pneumoniae Pneumonia in Childhood.

4.A Case of Myositis Ossificans Progressiva.

5.Studies on the amplification and detection of bovine leukosis proviral DNA by PCR and ECL techniques.

6.Clinical and Immunologic Studies on Epidemic Encephalitis.

7.Developmental Changes of Auditory Brainstem Responses in Children.

8.Serum erythropoietin and tumor necrosis factor ?in neoplasms, chronic inflammatory disorders, and iron deficiency anemias.

9.Small Dose Intrathecal Morphine for Post-cesarean Analgesia.

10.Short-term Effect of Intravitreal Bevacizumab Injection Preventing Panretinal Photocoagulation-Induced Macular Edema in Proliferative Diabetic Retinopathy.

Display Mode

Output Records

File Type